1. Search Result
Search Result
Results for "

AR

" in MedChemExpress (MCE) Product Catalog:

710

Inhibitors & Agonists

1

Screening Libraries

3

Fluorescent Dye

4

Biochemical Assay Reagents

20

Peptides

9

Inhibitory Antibodies

63

Natural
Products

18

Recombinant Proteins

65

Isotope-Labeled Compounds

15

Antibodies

5

Click Chemistry

19

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-12798C

    AR-13324 M1 metabolite

    PKC ROCK Cardiovascular Disease Neurological Disease
    AR-13503 (AR-13324 M1 metabolite) is the hydrolytic metabolite of AR-13324 mesylate. AR-13324 is a ROCK kinase and PKC inhibitor with anti-angiogenic and retinal health-improving effects, showing potential for use in retinal disease research .
    AR-13503
  • HY-N6703

    (+)-AR-Turmerone

    Apoptosis Neurological Disease Inflammation/Immunology Cancer
    ar-Turmerone ((+)-ar-Turmerone) is an orally active and major bioactive compound of the herb Curcuma longa with anti-tumorigenesis and anti-inflammatory activities. ar-Turmerone induces apoptosis in U937 cells. ar-Turmerone exerts positive modulation on murine DCs. ar-Turmerone induces NSC proliferation in vitro and in vivo, and can be used for various neurologic disorders study .
    ar-Turmerone
  • HY-19346

    ROCK Others
    AR-13324 analog mesylate is an analog of AR-13324. AR-13324 is an ROCK and norepinephrine transporter (NET) inhibitor .
    AR-13324 analog mesylate
  • HY-10547
    OSU-03012
    5 Publications Verification

    AR-12; PDK1 inhibitor AR-12

    PDK-1 Autophagy Cancer
    OSU-03012 (AR-12; PDK1 inhibitor AR-12) is a blood-brain permeable PDK-1 inhibitor with an IC50 of 5 μM .
    OSU-03012
  • HY-173373

    Ligands for Target Protein for PROTAC Androgen Receptor Cancer
    AR ligand-39, an orally active and selective androgen receptor (AR) antagonist, is a PROTAC target protein ligand (Ligand for Target Protein for PROTAC). AR ligand-39 can be used for synthesis PROTAC AR Degrader-10 (HY-173372) .
    AR ligand-39
  • HY-172624

    Ligands for Target Protein for PROTAC Cancer
    AR antagonist 14 is is a PROTAC target protein ligand (Ligands for Target Protein for PROTAC). AR antagonist 14 can be combined with VH 101-amide-piperidine-Pip-alkyne (HY-172625) to synthesize PROTAC degraders (ARD-69 (HY-114402)) .
    AR antagonist 14
  • HY-151266

    Androgen Receptor Cancer
    AR antagonist 4 (Compound 67-b) is an orally active androgen receptor (AR) antagonist with an IC50 of 246.6 nM against wt-AR, and is also an AR degrader with a DC50 of 2.84 μM .
    AR antagonist 4
  • HY-163510

    Androgen Receptor Cancer
    AR/AR-V7-IN-1 (Compound 20i) is an AR/ARV7 inhibitor (IC50 = 172.85 nM). AR/AR-V7-IN-1 potently inhibits cell growth with IC50 values of 4.87 and 2.07 μM in the LNCaP and 22RV1 cell lines, respectively. AR/AR-V7-IN-1 exhibits effective tumor growth inhibition in the 22RV1 xenograft study. AR/AR-V7-IN-1 can be used for the research of prostate cancer .
    AR/AR-V7-IN-1
  • HY-N6703R

    (+)-AR-Turmerone (StandARd)

    Apoptosis Neurological Disease Inflammation/Immunology Cancer
    ar-Turmerone (Standard) is the analytical standard of ar-Turmerone. This product is intended for research and analytical applications. ar-Turmerone ((+)-ar-Turmerone) is an orally active and major bioactive compound of the herb Curcuma longa with anti-tumorigenesis and anti-inflammatory activities. ar-Turmerone induces apoptosis in U937 cells. ar-Turmerone exerts positive modulation on murine DCs. ar-Turmerone induces NSC proliferation in vitro and in vivo, and can be used for various neurologic disorders study.
    ar-Turmerone (Standard)
  • HY-P991493

    RSV Infection
    AR-201 is a human IgG1 monoclonal antibody (mAb) targeting F, Fusion glycoprotein F0. AR-201 has anti-respiratory syncytial virus (RSV) activity. AR-201 can be used in lower respiratory tract illness (LRTI) research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).
    AR-201
  • HY-15564
    AR 231453
    1 Publications Verification

    GPR119 Metabolic Disease
    AR 231453 is a potent, specific and orally available GPR119 agonist. AR 231453 can stimulate β-cell replication and improve islet graft function s .
    AR 231453
  • HY-129761

    Others Inflammation/Immunology
    AR 17048 is a potent antirheumatic agent .
    AR 17048
  • HY-10512R

    AR 0133418 (StandARd); GSK 3β inhibitor VIII (StandARd); AR 014418 (StandARd)

    GSK-3 Metabolic Disease Cancer
    AR-A014418 (Standard) is the analytical standard of AR-A014418. This product is intended for research and analytical applications. AR-A014418 is a potent, selective and ATP-competitive GSK3β inhibitor (IC50=104 nM; Ki=38 nM) .
    AR-A014418 (Standard)
  • HY-N6703S

    (+)-AR-Turmerone-d3

    Isotope-Labeled Compounds Apoptosis Neurological Disease Inflammation/Immunology Cancer
    ar-Turmerone-d3 is the deuterium labeled ar-Turmerone. ar-Turmerone ((+)-ar-Turmerone) is an orally active and major bioactive compound of the herb Curcuma longa with anti-tumorigenesis and anti-inflammatory activities. ar-Turmerone induces apoptosis in U937 cells. ar-Turmerone exerts positive modulation on murine DCs. ar-Turmerone induces NSC proliferation in vitro and in vivo, and can be used for various neurologic disorders study .
    ar-Turmerone-d3
  • HY-168547S

    Parasite Infection
    AR89-d6 (Compound AR102) is a deuterated derivative of AR89 with oral activity. AR89-d6 demonstrates activity against S. mansoni, S. haematobium, and S. japonicum, and can be utilized for research on schistosomiasis .
    AR89-d6
  • HY-P991318

    Mucin Cancer
    AR20.5 is a human monoclonal antibody (mAb) targeting MUC1. AR20.5 increases the number of activated CD8 T cells, CD3+CD4−CD8−(DN) T cells, and mature dendritic cells in pancreatic tumor-bearing mice. AR20.5 can be used in anti-pancreatic cancer immunity research .
    AR20.5
  • HY-163641

    Molecular Glues Androgen Receptor E1/E2/E3 Enzyme Cancer
    AR Degrader-1 (Compound ML 2-9) is a molecular glue androgen receptor (AR) monovalent degrader. AR Degrader-1 degrades AR through DCAF16 (E3 ligase) without obvious cytotoxicity in LNCaP prostate cancer cells .
    AR Degrader-1
  • HY-133127

    Glucokinase Metabolic Disease
    AR453588 is a potent and orally bioavailable anti-diabetic glucokinase activator, with an EC50 of 42 nM. AR453588 shows anti-hyperglycemic activity .
    AR453588
  • HY-133127A

    Glucokinase Metabolic Disease
    AR453588 hydrochloride is a potent and orally bioavailable anti-diabetic glucokinase activator, with an EC50 of 42 nM. AR453588 hydrochloride shows anti-hyperglycemic activity .
    AR453588 hydrochloride
  • HY-170951

    Androgen Receptor Cancer
    AR antagonist 10 (Compound Y5) is potent and orally active androgen receptor (AR) antagonist with an IC50 of 0.04 μM. AR antagonist 10 demonstrates dual mechanisms of action, antagonizes AR by disrupting AR dimerization, and induces AR degradation via the ubiquitin-proteasome pathway. AR antagonist 10 exhibits excellent activity against variant drug-resistant AR mutants. AR antagonist 10 effectively suppresses the tumor growth of the LNCaP xenograft. AR antagonist 10 is potential to be used for drug-resistant prostate cancer .
    AR antagonist 10
  • HY-U00371

    Adrenergic Receptor Neurological Disease Endocrinology
    AR-​08 is an agonist of α2-adrenergic receptor, used for the treatment of attention deficit hyperactivety disorder (ADHD).
    AR-08
  • HY-116522
    AR420626
    3 Publications Verification

    Free Fatty Acid Receptor Histone Methyltransferase HDAC mTOR CaMK p38 MAPK Epigenetic Reader Domain GLUT nAChR TNF Receptor Metabolic Disease Inflammation/Immunology Cancer
    AR420626 is a selective agonist of free fatty acid receptor 3 (FFAR3) (IC50=117 nM). AR420626 has anti-inflammatory, anticancer and antidiabetic activities. AR420626 improves neurogenic diarrhea by inhibiting nAChR mediated neural pathways. AR420626 inhibits the growth of HepG2 xenografts and inhibits the proliferation of hepatoma cells by inducing apoptosis. AR420626 also suppresses allergic asthma and eczema and has the ability to activate GPR41 to increase Ca 2+ signal-mediated glucose uptake and improve diabetes .
    AR420626
  • HY-111151

    APAU

    Epoxide Hydrolase Infection Cardiovascular Disease Metabolic Disease
    AR9281 (APAU) is a potent, selective and orally active soluble epoxide hydrolase (s-EH) inhibitor. AR-9281 can inhibits human sEH (HsEH) and murine sEH (MsEH) with IC50 values of 13.8 nM and 1.7 nM, respectively. AR9281 can be used for the research of inflammation, hypertension and type 2 diabetes .
    AR-9281
  • HY-101106
    AR7
    5+ Cited Publications

    RAR/RXR Neurological Disease Cancer
    AR7 is an atypical RARA/RARα (retinoic acid receptor, alpha) antagonist. AR7 specifically activates chaperone-mediated-autophagy (CMA) activity without affecting macroautophagy .
    AR7
  • HY-170303

    Ligands for Target Protein for PROTAC Cancer
    AR ligand-32 is a target protein ligand, used for the synthesis of PROTAC AR Degrader-7 (HY-160221) .
    AR ligand-32
  • HY-147706

    Others Cancer
    Ar524 has higher inhibitory activity than the known transgenic inhibitor kifunensine. At the same time, ar524 inhibited low concentration (10 μ M) Spheroid formation of human malignant cells.
    AR524
  • HY-170450

    Androgen Receptor Ligands for Target Protein for PROTAC Endocrinology
    AR ligand-38 is the ligand for androgen receptor, that can be used for synthesis of PROTAC AR Degrader-9 (HY-170448) .
    AR ligand-38
  • HY-114602

    Monocarboxylate Transporter Inflammation/Immunology
    AR-C117977 is a potent monocarboxylate transporter (MCT1) inhibitor. AR-C117977 prolongs the survival of skin and heart sllograft. AR-C117977 inhibits the development of transplant arteriosclerosis in aortic allografts partially, but was unable to inhibit alloantibody production after transplantation. AR-C117977 shows potent immunosuppressive properties in vivo effectively preventing acute but not chronic allograft rejection in the mouse .
    AR-C117977
  • HY-160680

    Androgen Receptor Endocrinology
    AR antagonist 6 (compound 6i) is a diphenyl ether androgen receptor (AR) antagonist that binds AR at a concentration of 120 nM. AR antagonist 6 exhibits low toxicity and in vitro activity against the golden Syrian hamster ear model .
    AR antagonist 6
  • HY-12122

    NO Synthase Neurological Disease
    AR-C102222 is a spirocyclic fluoropiperidine quinazoline selective iNOS inhibitor. AR-C102222 can be used for the research of neuropathic pain .
    AR-C102222
  • HY-169967

    Ligands for Target Protein for PROTAC Cancer
    AR ligand-31 is a PROTAC target protein ligand that can be used to synthesize PROTAC AR Degrader-5 (HY-160547) .
    AR ligand-31
  • HY-135483A

    nAChR Neurological Disease
    AR-R17779 hydrochloride is a potent and selective full agonist of nAChR, with Kis of 92 and 16000 nM for α7 and α4β2 subtype, respectively. AR-R17779 hydrochloride can improve learning and memory in rats. AR-R17779 hydrochloride also has anxiolytic activity. AR-R17779 hydrochloride can reduce inflammation by activating antiinflammatory cholinergic (vagal) pathways .
    AR-R17779 hydrochloride
  • HY-111273

    Mas-related G-protein-coupled Receptor (MRGPR) Cardiovascular Disease
    AR244555 is a malate-aspartate shuttle (MAS) inverse agonist with IC50s of 186 nM and 348 nM in human and rat inositol phosphatase (IP) Gq coupling assays respectively. AR244555 has cardioprotective effects .
    AR244555
  • HY-163813

    Molecular Glues Androgen Receptor Cancer
    AR Degrader-2 (Compound 2) is a molecular glue that degrades androgen receptor (AR) with a DC50 of 0.3-0.5 μM in cell VCaP.
    AR Degrader-2
  • HY-173409

    Androgen Receptor Ser/Thr Protease Inflammation/Immunology
    AR antagonist 11 (Compound c2) is a selective AR antagonist with an IC50 of 0.019 μM. AR antagonist 11 is also effective against AR F877L/T878A mutant (IC50: 1.03 μM). AR antagonist 11 inhibits LNCaP cell proliferation and reduces PSA protein expression (IC50: 0.54 μM). AR antagonist 11 can be used for research of prostate cancer (PCa) .
    AR antagonist 11
  • HY-142923

    Androgen Receptor Cancer
    AR antagonist 2 (compound 58) is a potent androgen receptor (AR) inhibitor with an IC50 of 0.95 μM. AR antagonist 2 has the potential for cancer research .
    AR antagonist 2
  • HY-170330

    Ligands for Target Protein for PROTAC Androgen Receptor Cancer
    AR ligand-33 is the ligand for androgen receptor, that can be used for synthesis of PROTAC AR Degrader-8 (HY-170329) as the target protein ligand .
    AR ligand-33
  • HY-10512
    AR-A014418
    15+ Cited Publications

    AR 0133418; GSK 3β inhibitor VIII; AR 014418

    GSK-3 Metabolic Disease Cancer
    AR-A014418 is a potent, selective and ATP-competitive GSK3β inhibitor (IC50=104 nM; Ki=38 nM) .
    AR-A014418
  • HY-144127

    Androgen Receptor Cancer
    AR antagonist 3 is a potent and selective androgen receptor (AR) antagonist with an IC50 of 0.47 µM. AR antagonist 3 exhibits a dose-dependent decrease of the FRET signal (IC50= 18.05 μM). AR antagonist 3 shows effective inhibition on tumor growth when administered intratumorally .
    AR antagonist 3
  • HY-119993

    BMH-23

    DNA/RNA Synthesis Cancer
    AR03 (BMH-23) is an apurinic/apyrimidinic endonuclease 1 (Ape1) inhibitor with an IC50 of 2.1 µM. AR03 has low affinity for double-stranded DNA. AR03 potentiates the cytotoxicity of methyl methanesulfonate and temozolomide in SF767 cells .
    AR03
  • HY-160692

    Androgen Receptor Others
    AR antagonist 7 (86) is an androgen receptor (AR) antagonist that can be used in the research of hair loss .
    AR antagonist 7
  • HY-13265
    AR-42
    2 Publications Verification

    HDAC-42; OSU-HDAC42

    HDAC Autophagy Apoptosis Cancer
    AR-42 (HDAC-42; OSU-HDAC42) is a potent, orally bioavailable pan-HDAC inhibitor (IC50=16 nM). AR-42 induces growth inhibition, cell-cycle arrest, apoptosis, and activation of caspases-3/7. AR-42 promotes hyperacetylation of H3, H4, and alpha-tubulin, and up-regulation of p21. AR-42 shows cytotoxicity against various human cancer cell lines .
    AR-42
  • HY-157455

    Androgen Receptor Cancer
    AR antagonist 5 (compound 30a) is a selective androgen receptor (AR) antagonist with an IC50 value of 134.8 nM. AR antagonist 5 has favorable pharmacokinetic properties and shows a high skin exposure and low plasma exposure [1.
    AR antagonist 5
  • HY-159922

    Androgen Receptor Cancer
    AR antagonist 9 is an orally bioavailable selective androgen receptor (AR) antagonist that exerts anticancer effects by disrupting the dimerization of AR ligand-binding domains, showing potential for overcoming drug resistance in prostate cancer (PCa). Its AR antagonistic activity has an IC50 value of 0.051 μM, comparable to Enzalutamide (HY-70002) (IC50 = 0.060 μM). AR antagonist 9 demonstrated superior efficacy against ARF876L/T877A and ARW741C mutants compared to Enzalutamide (HY-70002). Furthermore, AR antagonist 9 exhibited favorable pharmacokinetic properties, with an oral bioavailability of F = 66.24% in rats. In the LNCaP xenograft mouse model, oral administration of AR antagonist 9 significantly inhibited tumor growth. AR antagonist 9 holds promise for research into overcoming PCa drug resistance .
    AR antagonist 9
  • HY-P1129

    Neuropeptide Y Receptor Neurological Disease
    AR-M1896 is a GalR2 selective agonist with a binding IC50 of 1.76 nM for rat GalR2. AR-M1896 can be used for the research of acute myocardial infarction and neuropathic pain .
    AR-M1896
  • HY-12122A

    NO Synthase Neurological Disease Inflammation/Immunology
    AR-C102222 hydrochloride is a potent, competitive, orally active and highly selective inducible nitric oxide synthase (iNOS) inhibitor, with an IC50 of 37 nM . AR-C102222 hydrochloride has antinociception and anti-inflammatory activities .
    AR-C102222 hydrochloride
  • HY-145709

    Androgen Receptor Cancer
    Ar-V7-IN-1 is a potent inhibitor of Ar-V7. AR-V7 is a hormone-independent splice variant of the androgen receptor. Ar-V7-IN-1 has the potential for the research of various indications, in particular cancers such as prostate cancer (extracted from patent WO2018114781A1, compound 43) .
    Ar-V7-IN-1
  • HY-B1114
    Gliquidone
    1 Publications Verification

    AR-DF 26

    Potassium Channel Metabolic Disease
    Gliquidone (AR-DF 26) is an anti-diabetic agent in the sulfonylurea class, used in the treatment of diabetes mellitus type 2.
    Gliquidone
  • HY-101039A

    Opioid Receptor Neurological Disease
    AR-M 1000390 hydrochloride is an exceptionally selective, potent δ opioid receptor agonist with an EC50 of 7.2±0.9 nM for δ agonist potency.
    AR-M 1000390 hydrochloride
  • HY-101039

    Opioid Receptor Neurological Disease
    AR-M 1000390 is an exceptionally selective, potent δ opioid receptor agonist with an EC50 of 7.2±0.9 nM for δ agonist potency.
    AR-M 1000390

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: